Abstract
Abstract In this study, preclinical evaluation and dosimetric estimation of [64Cu]Cu-BPAMD, as a new bone-seeking agent for PET imaging, was studied. [64Cu]Cu-BPAMD was produced with a specific activity of 8.7 GBq/µmol and radiochemical purity (R.P.) of >98 %. The HA binding results showed the binding of nearly all [64Cu]Cu-BPAMD complex to HA at about 15 mg. Biodistribution studies in the male Syrian rats indicated considerable accumulation in the bone with negligible uptake in the other organs. The bone surface and the bone marrow receiving 0.199 and 0.092 mGy/MBq, respectively, are the organs with the most absorbed dose. This study confirms the production of [64Cu]Cu-BPAMD with high R.P. showing high potential for PET-imaging of bone metastases. The lower absorbed dose of mainly human organs compared to 68Ga-BPAMD can be considered one of the advantages of this new radiolabeled compound.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
